Cargando…

Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar

OBJECTIVES: To evaluate an intervention to reduce the nocebo effect (NE) when switching from the originator infliximab (OI) to the infliximab biosimilar SB2 in chronic inflammatory rheumatic disease (CIRD). METHODS: An intervention was built with healthcare professionals (HPs) and a patient represen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petit, Juliette, Antignac, Marie, Poilverd, Rose-Marie, Baratto, Régine, Darthout, Sylvie, Desouches, Sandra, Louati, Karine, Deparis, Nathalie, Berenbaum, Francis, Beauvais, Catherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Education
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839879/ https://www.ncbi.nlm.nih.gov/pubmed/33495387 http://dx.doi.org/10.1136/rmdopen-2020-001396

Ejemplares similares

Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect
por: Rezk, Mourad F., et al.
Publicado: (2017)

The Clinical Implications of Nocebo Effects for Biosimilar Therapy
por: Colloca, Luana, et al.
Publicado: (2019)

Nocebo in Biosimilars and Generics in Neurology: A Systematic Review
por: Spanou, Ioanna, et al.
Publicado: (2019)

To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars
por: Rezk, Mourad F., et al.
Publicado: (2018)

The nocebo effect challenges the non-medical infliximab switch in practice
por: Boone, N. W., et al.
Publicado: (2018)

Correction to: To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars
por: Rezk, Mourad F., et al.
Publicado: (2018)

The role of the Nocebo effect in the use of biosimilars in routine rheumatology clinical practice
por: Kravvariti, Evrydiki, et al.
Publicado: (2019)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb
por: Bhat, Shubha, et al.
Publicado: (2020)

Biosimilar infliximab use in paediatric IBD
por: Richmond, Lisa, et al.
Publicado: (2018)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
por: Subedi, Smriti, et al.
Publicado: (2019)

PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Nocebo and pain: an overview of the psychoneurobiological mechanisms
por: Blasini, Maxie, et al.
Publicado: (2017)

Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
por: Kristensen, Lars Erik, et al.
Publicado: (2018)

The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies
por: Odinet, Johlee S., et al.
Publicado: (2018)

Fatigue in chronic inflammation - a link to pain pathways
por: Louati, Karine, et al.
Publicado: (2015)

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

Nocebo effects in clinical studies: hints for pain therapy
por: Klinger, Regine, et al.
Publicado: (2017)

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
por: Peng, Kuan, et al.
Publicado: (2023)

Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
por: Lerch, Thomas F., et al.
Publicado: (2019)

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
por: Peters, Bas J. M., et al.
Publicado: (2021)

Adherence patterns in naïve and prevalent use of infliximab and its biosimilar
por: Alanaeme, Chibuike J., et al.
Publicado: (2022)

Chronic Inflammatory Demyelinating Polyneuropathy After Therapy With Infliximab Biosimilar
por: Larson, Jessica, et al.
Publicado: (2023)

Placebo – Nocebo
por: Mosser, Astrid
Publicado: (2022)

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2019)

Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?
por: Fleischmann, Roy, et al.
Publicado: (2020)

Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion
por: Vimpolsek, Maja, et al.
Publicado: (2019)

Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab)
por: Hong, Juyong, et al.
Publicado: (2016)

Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade(®) (Infliximab)
por: Derzi, Mazin, et al.
Publicado: (2016)

Advanced assessment through intact glycopeptide analysis of Infliximab’s biologics and biosimilar
por: Kim, Hyejin, et al.
Publicado: (2022)

A descriptive analysis of real-world treatment patterns of innovator (Remicade(®)) and biosimilar infliximab in an infliximab-naïve Turkish population
por: Yazici, Yusuf, et al.
Publicado: (2018)

The nocebo effect of drugs
por: Planès, Sara, et al.
Publicado: (2016)

Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
por: Bergqvist, Viktoria, et al.
Publicado: (2018)

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab
por: Feagan, Brian G., et al.
Publicado: (2018)

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
por: Milassin, Ágnes, et al.
Publicado: (2019)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
por: Moorkens, Evelien, et al.
Publicado: (2020)

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
por: Ebbers, Hans C., et al.
Publicado: (2020)

Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
por: Reinisch, Walter, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f3dlnj2b3ipd5sql9mo1p6jpqu